Therapeutic effects and tolerance of an extempore combination of an antibacterial, an anti-inflammatory, and an antimycotic cream in skin diseases of various origins.
Forty out-patients suffering from a variety of skin diseases were treated over a period of 7 to 14 days (mean 9.6 days) with twice-daily applications of an extempore combination of sodium fusidate, clobetasone butyrate and ketoconazole creams. The severity of symptoms was assessed before, after 5 days and at the end of treatment and an overall evaluation made of response to therapy. The findings indicated that there was clinical cure or significant improvement in 37 (92.5%) of the patients, with excellent tolerance and no reports of any adverse reactions.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002990:Clobetasol / Q000031:analogs & derivatives / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D005672:Fusidic Acid / Q000627:therapeutic use; D006801:Humans; D007654:Ketoconazole / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012871:Skin Diseases / Q000188:drug therapy* / Q000382:microbiology
D000891:Anti-Infective Agents, Local; D000893:Anti-Inflammatory Agents; D000935:Antifungal Agents; D004338:Drug Combinations; D005672:Fusidic Acid; C010893:clobetasone butyrate; D002990:Clobetasol; D007654:Ketoconazole